Amino Acid - Maple Syrup Disease, Plasma

Amino Acid - Maple Syrup Disease, Plasma is a specialized blood test used to measure plasma amino acids associated with Maple Syrup Urine Disease (MSUD). The test primarily evaluates the branched-chain amino acids leucine, isoleucine, and valine, together with alloisoleucine, an important diagnostic marker for MSUD.

MSUD is a rare inherited metabolic disorder in which the body cannot properly break down branched-chain amino acids. This occurs because of reduced activity of the branched-chain alpha-ketoacid dehydrogenase complex. As a result, branched-chain amino acids and their corresponding ketoacids can accumulate to toxic levels, particularly affecting the brain and nervous system. Early identification and treatment are essential to reduce the risk of neurological injury, metabolic crisis, coma, and other serious complications.

Benefits of the Test

• Measures branched-chain amino acids associated with MSUD.
• Detects abnormal alloisoleucine in plasma.
• Supports confirmation of an abnormal newborn screening result.
• Helps diagnose classic, intermediate, and intermittent forms of MSUD.
• Assists in monitoring dietary treatment and metabolic control.
• Supports assessment during illness or suspected metabolic crisis.
• Helps guide individualized nutritional and medical management.
• Provides reliable laboratory-based metabolic evaluation.

Why Doctors Recommend This Test

Doctors recommend this test when a newborn screening result suggests MSUD or when an infant develops poor feeding, vomiting, lethargy, abnormal muscle tone, seizures, unusual movements, altered consciousness, or a characteristic sweet or maple-syrup-like odor. It is also used for individuals with a family history of MSUD and for diagnosed patients who require regular monitoring of branched-chain amino acid levels during dietary treatment, illness, or metabolic decompensation.

Preparation Before Test

• A plasma blood sample is required for testing.
• Fasting requirements depend on the patient's age, clinical condition, and laboratory protocol.
• Do not delay urgent testing in a symptomatic newborn or patient to obtain a fasting specimen.
• Do not change the prescribed diet or medical formula unless instructed by the metabolic specialist.
• Inform the doctor about medicines, supplements, medical foods, and recent dietary intake.
• Provide details of newborn screening results and family history of metabolic disease.
• For monitoring, collect the sample at the time recommended by the treating specialist.
• The plasma must be separated, stored, and transported according to laboratory instructions.
• Follow all sample-collection instructions provided by the healthcare team and laboratory.

Normal Reporting Time

Most Amino Acid - Maple Syrup Disease, Plasma reports at Focus Diagnostics are initiated within 2–3 hours of sample receipt for processing and specialized metabolic testing workflow preparation. Final amino acid measurement, alloisoleucine evaluation, interpretation, quality review, and reporting are generally completed within several working days, depending on laboratory protocols and quality-assurance requirements. Suspected metabolic emergencies require immediate medical evaluation and should not wait for routine reporting.

Who Should Take This Test?

This test may be recommended for:

• Newborns with an abnormal MSUD screening result.
• Infants with poor feeding, vomiting, lethargy, or abnormal muscle tone.
• Patients with seizures, altered consciousness, or suspected metabolic encephalopathy.
• Individuals with a sweet or maple-syrup-like odor in urine or earwax.
• Children or adults with suspected intermittent MSUD.
• People with a sibling or family member diagnosed with MSUD.
• Patients already diagnosed with MSUD who require treatment monitoring.
• Individuals being assessed during illness or suspected metabolic decompensation.

Detailed Information

Leucine, isoleucine, and valine are essential branched-chain amino acids obtained from dietary protein. Normally, these amino acids are broken down through a series of enzymatic reactions so that the body can use them for energy, growth, and tissue maintenance.

In MSUD, the branched-chain alpha-ketoacid dehydrogenase complex does not function normally. This causes leucine, isoleucine, valine, and their corresponding ketoacids to accumulate in the blood and tissues. High leucine levels are particularly harmful to the brain and can cause cerebral edema, neurological dysfunction, and metabolic encephalopathy.

MSUD is generally inherited in an autosomal recessive pattern. This means that an affected individual usually inherits one altered gene copy from each parent. The disorder may involve pathogenic variants in genes such as BCKDHA, BCKDHB, or DBT. Molecular genetic testing may be recommended to confirm the diagnosis and identify the specific genetic cause.

Classic MSUD usually presents during the first days of life. Initially, the newborn may appear healthy but can later develop feeding difficulty, vomiting, lethargy, abnormal movements, changes in muscle tone, seizures, or progressive loss of consciousness. A sweet odor resembling maple syrup may be noticed in urine, sweat, or earwax, but the absence of this odor does not rule out the condition.

Intermediate and intermittent forms may present later in childhood or adulthood. Some individuals may remain relatively well until infection, fasting, surgery, or another catabolic stress triggers a sudden rise in branched-chain amino acid levels. Symptoms may include confusion, poor coordination, vomiting, behavioral changes, or neurological deterioration.

Plasma amino acid analysis typically demonstrates elevated leucine, isoleucine, and valine. Alloisoleucine is considered a particularly sensitive and specific biochemical marker for MSUD. Results must be interpreted according to the patient's age, symptoms, dietary treatment, timing of collection, and clinical condition.

An abnormal newborn screening result is not by itself a final diagnosis. Follow-up quantitative plasma amino acid analysis and alloisoleucine measurement are required. Additional investigations may include urine organic acid analysis, branched-chain ketoacid assessment, enzyme studies, and molecular genetic testing.

Once MSUD is diagnosed, regular plasma amino acid testing is essential for monitoring treatment. Management generally involves controlled dietary leucine intake, specialized branched-chain-amino-acid-free medical formula, and carefully monitored supplementation of isoleucine and valine. Treatment should always be supervised by an experienced metabolic specialist and dietitian.

During fever, infection, reduced food intake, surgery, or other illness, protein breakdown within the body may rapidly increase leucine levels. Patients with MSUD can deteriorate quickly during these periods. Symptoms such as repeated vomiting, unusual sleepiness, confusion, loss of balance, seizures, or reduced consciousness require urgent medical care.

At Focus Diagnostics, Amino Acid - Maple Syrup Disease, Plasma testing is performed using advanced amino acid analytical technologies, validated metabolic testing methodologies, and stringent quality-assurance standards to provide accurate, reliable, and clinically meaningful results.